Peritransplantation Use of Ruxolitinib in Myelofibrosis.
Biol Blood Marrow Transplant
; 26(12): 2177-2180, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-32818555
ABSTRACT
Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transplante de Células-Tronco Hematopoéticas
/
Mielofibrose Primária
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article